Number of petitions slumps in the first quarter as petitioners and patent owners come to terms with 12 months of change at the board
What the latest Federal Circuit 101 decision means for the medical diagnostics sector.
Storm clouds are gathering over the most talked about company in the telecoms sector but as we embark on a new era of mobile technology, Huawei still enjoys a number of notable advantages.
Regulations in the special economic zone once known primarily as a den of piracy will allow fast-track administrative injunctions and impose stiff penalties on repeat infringers
China’s healthcare sector is booming and while the patent system has developed considerably in recent years, pharmaceutical companies should still think carefully about how to protect their rights.
New USPTO guidelines on subject matter eligibility have been met with praise from many patent owners but may diverge from US Supreme Court precedent.
Following the court’s Abraxis decision, life sciences face a more restrictive interpretation of which products qualify for supplementary protection certificates.
CNIPA has promised to reduce examination times, but users are more concerned about quality. Agency's deputy director waves off the suggestion that 90% of its issued patents are 'junk'
The new IP tribunal shows that China is accepting its responsibilities as a world leader in IP policy, says the former US Federal Circuit chief judge.
As back and forth in landmark patent fight continues USPTO Director Iancu admits clarification needed on controversial 2013 SEP policy statement
With China emerging as a crucial market for the life sciences, it is crucial that those in the industry keep up with the swift pace of IP reforms and other changes – especially when it comes to enforcement.
The Japan Patent Office has published a series of case examples that explain its approach to handling filings related to inventions in the field of artificial intelligence
Thom Tillis, chair of the US Senate’s IP subcommittee, also raises prospect of codifying reforms issued by USPTO Director Andrei Iancu
After nine years of legal manoeuvring, the US chipmaker has won approval for its licensing practices in Japan. But in other parts of the region, antitrust doubts remain
US-China rows over trade secrets have made headlines the world over and highlighted Big Tech’s frustration with aspects of the Chinese IP regime. It is unclear whether any suggested solutions will assuage concerns